Verana Health aggregates de-identified electronic health record data from more than 20,000 clinicians to create high-quality real-world evidence datasets for the life-sciences industry. Its AI-powered curation technology structures and validates data in ophthalmology, urology, and neurology, and, through its merger with COTA, now expands deeply into oncology. The combined company accesses more than 95 million patient records, including over 10 million oncology patients, and partners with an extended network of 30+ academic medical centers. These datasets support biopharma customers across clinical trial design, regulatory submissions, health economics and outcomes research, and market-access work, while also offering advisory services for clinicians’ MIPS submissions. The integration of COTA’s high-fidelity oncology data is expected to speed up data processing and deliver ready-to-analyze datasets to research teams. Verana Health currently serves 17 of the world’s top 20 biopharma companies, underscoring strong commercial traction. The newly raised capital will fund platform expansion and deeper clinical data capabilities. No revenue figures or profitability metrics were disclosed in the article.

Total raised

$340M

Funding rounds

5

Latest round

Equity

Latest activity

Jan 2026